News

The Pharma Letter13h
ImCheck doubles up on orphan designations for ICT01 in AML
French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...
The Manila Times4d
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...
Targeted Oncology4d
Optimizing AML Treatment: ICT01 Receives FDA Orphan Drug Designation
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Pharmabiz1d
US FDA grants orphan drug designation to ImCheck’s ICT01 for treatment of acute myeloid leukaemia
Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...
The Manila Times4d
Buxton, Elevar, and Audiense Unite Under a New Brand: Audiense
Fort Worth, TX, July 18, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE ...
Targeted Oncology18d
Advancements in Essential Thrombocythemia: Targeting External Proteins
Aaron T. Gerds, MD, discusses the unmet needs in the treatment of essential thrombocythemia, as well as novel methods for approaching disease treatment.